MX2015012184A - Compuestos acilaminocicloalquilos adecuados para el tratamiento de los trastornos que responden a la modulacion del receptor d3 de la dopamina. - Google Patents
Compuestos acilaminocicloalquilos adecuados para el tratamiento de los trastornos que responden a la modulacion del receptor d3 de la dopamina.Info
- Publication number
- MX2015012184A MX2015012184A MX2015012184A MX2015012184A MX2015012184A MX 2015012184 A MX2015012184 A MX 2015012184A MX 2015012184 A MX2015012184 A MX 2015012184A MX 2015012184 A MX2015012184 A MX 2015012184A MX 2015012184 A MX2015012184 A MX 2015012184A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- fluorinated
- group
- alkoxy
- dopamine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title abstract 2
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000003566 oxetanyl group Chemical group 0.000 abstract 2
- 125000005475 oxolanyl group Chemical group 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786869P | 2013-03-15 | 2013-03-15 | |
| US201361918524P | 2013-12-19 | 2013-12-19 | |
| PCT/EP2014/055062 WO2014140246A1 (en) | 2013-03-15 | 2014-03-14 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012184A true MX2015012184A (es) | 2016-05-16 |
Family
ID=50280387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012184A MX2015012184A (es) | 2013-03-15 | 2014-03-14 | Compuestos acilaminocicloalquilos adecuados para el tratamiento de los trastornos que responden a la modulacion del receptor d3 de la dopamina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9388148B2 (enExample) |
| EP (1) | EP2970146B1 (enExample) |
| JP (1) | JP2016514117A (enExample) |
| CN (1) | CN105339357A (enExample) |
| AU (1) | AU2014230215A1 (enExample) |
| BR (1) | BR112015021471A2 (enExample) |
| CA (1) | CA2902656A1 (enExample) |
| MX (1) | MX2015012184A (enExample) |
| TW (1) | TW201514154A (enExample) |
| UY (1) | UY35420A (enExample) |
| WO (1) | WO2014140246A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| AR095264A1 (es) * | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| CA3089498A1 (en) | 2018-01-26 | 2019-08-01 | Shionogi & Co., Ltd. | Condensed ring compounds having dopamine d3 receptor antagonistic effect |
| WO2020156312A1 (zh) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种多环类衍生物调节剂、其制备方法和应用 |
| CN112239433B (zh) * | 2019-07-17 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
| US12617759B2 (en) * | 2019-10-29 | 2026-05-05 | Shanghai Hansoh Biomedical Co., Ltd. | Modifier of four-membered ring derivative, preparation method and application thereof |
| TWI873212B (zh) * | 2019-10-29 | 2025-02-21 | 大陸商上海翰森生物醫藥科技有限公司 | 四員環類衍生物調節劑、其製備方法和應用 |
| CN113754580B (zh) | 2020-06-05 | 2023-04-25 | 上海中泽医药科技有限公司 | 一种吡啶吗啉类化合物、其制备方法及其应用 |
| TW202302576A (zh) * | 2021-04-28 | 2023-01-16 | 大陸商上海翰森生物醫藥科技有限公司 | 含哌嗪多環類衍生物的鹽及晶型及其製備方法和應用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| JP2004359689A (ja) | 2003-06-05 | 2004-12-24 | Abbott Gmbh & Co Kg | ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物 |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| ES2340941T3 (es) | 2004-08-09 | 2010-06-11 | ABBOTT GMBH & CO. KG | Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina. |
| DE102004061593A1 (de) * | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| CA2691082A1 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| CN102159557A (zh) * | 2008-09-22 | 2011-08-17 | 弗·哈夫曼-拉罗切有限公司 | 哌嗪d3和5-ht2a受体调节剂 |
| AU2009296047A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine D3 receptors |
| US8586579B2 (en) * | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8470828B2 (en) | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
-
2014
- 2014-03-13 UY UY0001035420A patent/UY35420A/es not_active Application Discontinuation
- 2014-03-14 JP JP2015562180A patent/JP2016514117A/ja active Pending
- 2014-03-14 MX MX2015012184A patent/MX2015012184A/es unknown
- 2014-03-14 EP EP14710261.0A patent/EP2970146B1/en active Active
- 2014-03-14 BR BR112015021471A patent/BR112015021471A2/pt not_active IP Right Cessation
- 2014-03-14 AU AU2014230215A patent/AU2014230215A1/en not_active Abandoned
- 2014-03-14 CA CA2902656A patent/CA2902656A1/en not_active Abandoned
- 2014-03-14 CN CN201480026453.XA patent/CN105339357A/zh active Pending
- 2014-03-14 TW TW103109325A patent/TW201514154A/zh unknown
- 2014-03-14 US US14/213,169 patent/US9388148B2/en active Active
- 2014-03-14 WO PCT/EP2014/055062 patent/WO2014140246A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014140246A1 (en) | 2014-09-18 |
| BR112015021471A2 (pt) | 2017-07-18 |
| EP2970146B1 (en) | 2017-11-01 |
| TW201514154A (zh) | 2015-04-16 |
| CN105339357A (zh) | 2016-02-17 |
| AU2014230215A1 (en) | 2015-09-03 |
| CA2902656A1 (en) | 2014-09-18 |
| JP2016514117A (ja) | 2016-05-19 |
| US9388148B2 (en) | 2016-07-12 |
| US20140303176A1 (en) | 2014-10-09 |
| UY35420A (es) | 2014-10-31 |
| EP2970146A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005093A (es) | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3. | |
| UY35420A (es) | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 | |
| AR131188A2 (es) | Proceso para producir derivado de diazabiciclooctano y su intermediario | |
| JOP20200225A1 (ar) | مشتق كوينولين عالي النقاء وطريقة لإنتاجه | |
| PH12014502866A1 (en) | Fungicidal heterocyclic carboxamides | |
| NZ631337A (en) | Prodrugs of fumarates and their use in treating various diseases | |
| MX2015014666A (es) | Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares. | |
| PH12014502413A1 (en) | Cyclic bridgehead ether dgat1 inhibitors | |
| JO3202B1 (ar) | مركبات 4- فينيل- بيريدين بها استبدال لعلاج الامراض ذات الصلة بمستقبل nk-1 | |
| MX2009008781A (es) | Derivados de ciclohexano espirociclicos. | |
| PH12017500513A1 (en) | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b | |
| WO2014140784A3 (en) | Buprenorphine analogs | |
| JO3509B1 (ar) | معدلات p2x7 | |
| IN2014MN01521A (enExample) | ||
| IN2015MN00404A (enExample) | ||
| PH12016501507A1 (en) | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof | |
| IN2014KN00889A (enExample) | ||
| IN2015DN00957A (enExample) | ||
| MY172860A (en) | Dimethyl-benzoic acid compounds | |
| IN2014DN10617A (enExample) | ||
| PH12015501962A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
| CR20140337A (es) | Control de la concentración de etanol durante la fermentación de gas de síntesis. | |
| AR109467A1 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño | |
| AU2014371081A1 (en) | Polyoxalates and a Process for the Production Thereof | |
| PH12014502845A1 (en) | Novel cholecystokinin receptor ligands |